Alzamend Neuro (ALZN) vs Evogene (EVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alzamend Neuro is the larger company by market cap ($6.5 million vs $6.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | EVGN |
|---|---|---|
| Share price | $1.34 | $0.3985 |
| Market cap | $6.47M | $6.30M |
| 1-day change | -2.19% | -2.95% |
| EPS (TTM) | $-2.30 | $-1.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $1.49 |
| 52-week low | $0.84 | $0.35 |
| Distance from 52-week high | -50.00% | -73.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1840.30% | +439.52% |
| Average volume | 88.67K | 1.50M |
| Shares outstanding | 4.83M | 15.80M |
| Employees | 4 | 38 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Alzamend Neuro in Health Care and Evogene in Industrials.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Evogene
EVGN stock →Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications.
Industrials · Agricultural Chemicals · 38 employees
ALZN vs EVGN FAQ
Which is bigger, Alzamend Neuro or Evogene?
Alzamend Neuro (ALZN) is larger, with a market capitalization of $6.47M compared with $6.30M for Evogene (EVGN).
Are Alzamend Neuro and Evogene in the same industry?
No. Alzamend Neuro is in the Health Care sector, while Evogene is in Industrials.